Lilly and Adocia partner on ultra-rapid insulin for diabetes

Eli Lilly and French biotech Adocia are to develop an ultra-rapid insulin, BioChaperone Lispro, for type 1 and type 2 diabetes. BioChaperone Lispro is based on Adocia’s technology and is currently in phase Ib studies.

The product aims to optimise glucose levels during and after meals and could bring greater flexibility in the timing of insulin injections, lower variability of post-meal blood glucose elevations, lower rates of hypoglycemia and better overall glucose control.

Under the terms of the agreement, Lilly will develop, manufacture and commercialise BioChaperone Lispro in the deal, which could be worth up to $570 million. Adocia will receive an upfront fee of $50 million with potential future payments of up to $280 million if the product reaches certain development and regulatory milestones and sales milestones up to $240 million. A concentrated formulation of BioChaperone Lispro is also part of the agreement.

Enrique Conterno, president, Lilly Diabetes said that an ultra-rapid acting insulin would be a “natural fit” in the company’s growing portfolio. In September, the Lilly-Boehringer Ingelheim Alliance had its fourth diabetes product approved in the EU – a biosimilar of Sanofi’s blockbuster Lantus, known as Abasria in Europe.

Adocia retains the right to develop and licence its insulin programmes unrelated to prandial ultra-rapid insulin.


Insulin glargine biosimilar approved in Europe

Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.